Royalty Pharma Declares Third Quarter 2024 Dividend
July 17 2024 - 4:15PM
The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has
approved the payment of a dividend for the third quarter of 2024 of
$0.21 per Class A ordinary share.
The dividend will be paid on September 13, 2024, to shareholders
of record at the close of business on August 16, 2024.
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of
biopharmaceutical royalties and a leading funder of innovation
across the biopharmaceutical industry, collaborating with
innovators from academic institutions, research hospitals and
non-profits through small and mid-cap biotechnology companies to
leading global pharmaceutical companies. Royalty Pharma has
assembled a portfolio of royalties which entitles it to payments
based directly on the top-line sales of many of the industry’s
leading therapies. Royalty Pharma funds innovation in the
biopharmaceutical industry both directly and indirectly – directly
when it partners with companies to co-fund late-stage clinical
trials and new product launches in exchange for future royalties,
and indirectly when it acquires existing royalties from the
original innovators. Royalty Pharma’s current portfolio includes
royalties on more than 35 commercial products, including Vertex’s
Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s
Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson &
Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’
Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 17
development-stage product candidates. For more information, visit
www.royaltypharma.com.
Royalty Pharma Investor Relations and
Communications
+1 (212) 883-6637ir@royaltypharma.com
Royalty Pharma (NASDAQ:RPRX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Royalty Pharma (NASDAQ:RPRX)
Historical Stock Chart
From Aug 2023 to Aug 2024